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Summary 
 To study the effects of the subcutaneous injection of 
glucagon and/or oral administration of glycerol on blood 
metabolites and hormones of Holstein dairy cows induced 
with fatty liver disease, twenty multiparous cows were fed a 
dry cow ration supplemented with 12 kg of cracked corn 
during the dry period to increase the likelihood of fatty liver 
disease development. Cows with a body condition score 
(BCS) of ≥ 3.5 points (0-5 scale) were randomly assigned to 
one of four treatment groups--saline, glucagon, glucagon 
plus glycerol, and glycerol. Following treatment, serial 
blood samples were collected to determine the effect of 
glucagon and/or glycerol on blood composition. Glucagon 
injection alone increased postpartal plasma glucose, 
glucagon, and insulin and decreased plasma NEFA and 
TAG. Glucagon plus glycerol treatment increased and 
sustained postpartal plasma glucose and insulin and 
decreased postpartal plasma NEFA and TAG. 
Administration of glycerol alone increased plasma glucose 
and decreased plasma NEFA during the postpartal period. 
Early postpartal treatment of cows with glucagon and/or 
glycerol increased plasma glucose and decreased plasma 
NEFA. This response would suggest that these treatments 
would decrease the likelihood of fatty liver disease in dairy 
cows. 
 
Introduction 
 Dairy cows that are obese or over-conditioned during 
the periparturient period are susceptible to a complex of 
metabolic and infectious diseases known as fat cow 
syndrome. Fat cow syndrome is well known to commence 
as fatty liver disease (FLD) before it exacerbates to other 
interrelated metabolic disorders such as ketosis and milk 
fever (decreased plasma calcium). Infectious sequelae to 
fatty liver disease include mastitis and metritis often 
associated with retained placenta. Other complications 
commonly seen with disease include left displaced 
abomasum and laminitis.  
 Fatty liver disease affects cows in the late prepartal (1 
wk before calving) and early postpartal periods (up to 2 wk 
after calving). The severity of FLD is often classified on the 
basis of the percentage of accumulated triacylglycerol 
(TAG) in the liver to assess the potential for deleterious 
effects to the health, productivity (kg of milk), and 
reproductivity of dairy cows. 
 Extensive studies have been undertaken to unravel the 
etiology of fatty liver disease as the underlying cause of fat 
cow syndrome. During the final weeks that immediately 
preceding parturition, feed intake progressively decreases to 
about 30% of normal on the day of parturition. This sharp 
decrease in feed intake is accompanied with an increased 
periparturient energy requirement to facilitate colostrum 
production. This results in a negative energy balance. To 
accommodate this energy deficit, it is essential for the cow 
to mobilize body fat reserves. Lipolysis is upregulated and 
nonesterified fatty acids (NEFA) from adipose tissue 
overwhelm the liver. Part of NEFA is esterified to be 
converted into triacylglycerol (TAG) that accumulate in the 
liver, causing fatty liver disease symptoms. It has been 
hypothesized that finding a preventative for fatty liver will 
likely prevent other interrelated metabolic disorders and 
infectious diseases during the peripartal (around calving) 
period. 
 Cows suffering fatty liver are treated similarly to cows 
affected with ketosis. In mild cases, they are treated with 
oral glucose precursors such as propylene glycol. In extreme 
cases, they are treated with intravenous dextrose infusions 
accompanied by intramuscular glucocorticoid injections. As 
a preventative against fatty liver disease and ketosis, 
glycerol mixed with feed has been evaluated. Glycerol 
drenches also have been assessed to alleviate ketosis. 
 Therapy of FLD is frustrating and rarely effective. A 
member of our research group recently demonstrated that 
continuous intravenous infusion of glucagon is efficacious 
in alleviating the fatty liver-ketosis complex in Holstein 
dairy cows. Nonetheless, intravenous injection is considered 
impractical in a dairy farm setting. It was subsequently 
demonstrated that subcutaneous injections of glucagon 
starting at d 8 postpartum alleviated fatty liver-ketosis 
complex symptoms from experimentally affected cows. 
More recently, we have shown that subcutaneous glucagon 
injections on d (1) prevent development of ketosis. The 
biochemical basis by which glucagon and/or glycerol exert 
their preventative action, however, is not fully understood. 
The objective of this study was to understand the 
biochemical basis by which glucagon and/or glycerol 
prevent fatty liver disease. 
 The ultimate goal of this study is to provide the U.S. 
farmers with a slow-release subcutaneous implant of 
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glucagon and/or a glycerol feeding protocol as an effective 
tool for treating fatty liver disease in dairy cows.   
 
Materials and Methods 
 Twenty multiparous (more than 2 calves) Holstein dairy 
cows with BCS of 3.5 or better were selected during the dry 
period. Cows were randomly assigned to one of four 
treatment groups that received the following treatments: 
1. Control group: Cows (n=4), starting at 6:00 h on d (1) 
postpartum (after calving), received 60 mL of saline (pH 
10.25) subcutaneously at 8 h intervals for 14 days. 
2. Glucagon group: Cows (n=4), starting at 6:00 h on d (1) 
postpartum, received 5 mg of glucagon dissolved in 60 mL 
of saline (pH = 10.25) subcutaneously at 8 h interval for 14 
days and once on d (15) postpartum. 
3. Glycerol group: Cows (n = 6), starting at 6;00 h on d (1) 
postpartum,  received 500 mL of glycerol diluted with 100 
mL of water orally once daily for 14 days. 
4. Glucagon-glycerol group: Cows (n=6), starting at 6:00 h 
on d (1) postpartum, received 5 mg of glucagon dissolved in 
60 mL of saline (pH=10.25) subcutaneously at 8 h intervals 
for 14 days and once on d (15) plus 500 mL of glycerol 
diluted with 100 mL of water once daily at 6:00 h.  
 Blood samples were collected on d (1), d (7), and d (13) 
postpartum (after calving) using a jugular catheter. Twenty 
milliliters of blood were collected into two tubes containing 
Na-EDTA at 15, 10, 5 min before administering each 
treatment and then at 15, 30, 45, 60, 80, 100, 120, 150, 180, 
210, 240, 300, 360, 420, and 480 min after treatment.  
Tubes were placed on ice until plasma was separated by 
centrifugation at 500 x g. Plasma was stored at – 200for 
subsequent analyses. 
 
Results and Discussion 
     We hypothesized that glucagon, glycerol, or glucagon 
plus glycerol could be administered to early postpartal cows 
to alleviate or prevent fatty liver disease. This clinical action 
is likely achieved by improving the energy status of the 
affected dairy cow. Our results have corroborated this 
hypothesis. 
 Glucagon, glycerol, and glucagon plus glycerol 
treatments increased plasma glucose concentration (figures 
1, 2, and 3). Glucagon plus glycerol treatment dramatically 
increased plasma glucose concentrations 50 % on d (1),  
d (7), and d (13) postpartum by more than 40 mg/dL greater 
than that of the control group and maintained it at an 
elevated concentration for longer time than did other 
treatments (figures 1 and 3). Glucagon treatment did not 
affect plasma NEFA concentration on d (1), but it did on  
d (7) an d (13) (figures 4, 5, and 6). Glucagon plus glycerol 
decreased plasma NEFA concentrations and maintained 
lower NEFA for longer time than other treatments on d (1) 
postpartum. Plasma NEFA concentration, however, was 
decreased by glucagon plus glycerol and glycerol treatments 
on all three sampling days. Glycerol treatment maintained 
plasma NEFA low for longer time than did glucagon plus 
glycerol treatment on d (7) and (13) postpartum (figures 5 
and 6).  
Glucagon is a potent glycogenolytic hormone that 
activates glycogen phosphorylase that causes glycogen to 
release glucose. Glucagon also increases gluconeogenesis 
by increasing liver uptake of amino acids that are used as a 
glucose precursor and thus further increase plasma glucose 
and by increasing the concentration of rate-limiting 
gluconeogenesis enzymes. 
Glycerol is an efficient glucogenic substrate (can be 
converted to glucose) because it enters the gluconeogenesis 
pathway at the triose phosphate level; glycerol, therefore, is 
not affected by the rate-limiting enzymes 
phosphoenolpyruvate carboxykinase and pyruvate  
carboxylase. Glycerol can increase plasma glucose in the 
absence of propionate coming from rumen fermentation at 
time of decreased feed intake. 
 Glucagon treatment increased plasma glucagon 
concentration (figure 7, 8, and 9). Also, glucagon treatment 
increased plasma insulin on d (7) and d (13) postpartum but 
only slightly on d (1) (figures 10, 11 and 12). 
 Glucagon, glycerol, and glucagon plus glycerol 
increased plasma glucose. This response necessitates plasma 
insulin to increase. The increase in plasma insulin is an 
essential signal that indicates energy abundance. Insulin 
activates glucose uptake and storage by muscles and adipose 
tissues (lipogenesis). Insulin also simulates ion uptake such 
as K+ and PO4 -3 and amino acid uptake and protein 
synthesis. Insulin also is needed to restrain metabolic 
processes that release stored body energy such as lipolysis, 
ketogenesis, and glycogenolysis. All of these responses 
suggest that glucagon, glycerol, and glucagon plus glycerol 
stimulate insulin release that could, in part, cause the 
metabolic responses that prevent the development of fatty 
liver by glucagon as shown in earlier research. 
 
Conclusion 
 Glucagon, glycerol, and glucagon plus glycerol 
decreased plasma NEFA concentration and increased 
plasma glucose. Glucagon treatment also elevated plasma 
insulin concentration.  These metabolic responses may 
explain why glucagon treatment in previous research 
decreased fatty liver development. 
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Figure 1. Effect of treatments on plasma  
glucose concentration on d (1) postpartum.  
Glucagon, glycerol, and glucagon plus glycerol  
(greatest stimulus) treatments increased plasma 
glucose. 
 
 
Plasma glucose d (7) 
 
-50 0 50 100 150 200 250 300 350 400 450 500
50
60
70
80
90
100
110
Pl
as
m
a 
gl
uc
os
e 
d 
(7
), 
m
g/
dL
Time relative to treatment, min
 Saline
 Glucagon
 Glycerol
 GlucGlyc
 
 
Figure 2. Effect of treatments on plasma glucose 
concentration on d (7) postpartum. Glucagon, 
glycerol, and glucagon plus glycerol increased plasma 
glucose.  
 
 
 
Plasma glucose d (13) 
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Figure 3. Effect of treatments on plasma glucose 
concentration on d (13) postpartum. Glucagon, 
glycerol, glucagon plus glycerol increased plasma 
glucose. 
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Figure 4. Effect of treatments on plasma NEFA 
concentration on d (1) postpartum. Glucagon, 
glycerol, glucagon plus glycerol decreased plasma 
NEFA. 
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Figure 5. Effect of treatments on plasma NEFA 
concentration on d (7) postpartum. Glucagon, 
glycerol, and glucagon plus glycerol decreased plasma 
NEFA. 
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Figure 6. Effect of treatments on plasma NEFA 
concentration on d (13) postpartum. Glucagon, 
glycerol, and glucagon plus glycerol decreased plasma 
NEFA. 
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Figure 7. Effect of glucagon treatment on plasma 
glucagon concentration on d (1) postpartum. Glucagon 
treatment increased plasma glucagon. 
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Figure 8. Effect of glucagon treatment on plasma 
glucagon concentration on d (7) postpartum. Glucagon 
treatment increased plasma glucagon concentration  
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Figure 9. Effect of glucagon treatment on plasma 
glucagon concentration on d (13) postpartum. 
Glucagon treatment increased plasma glucagon. 
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Figure 10. Effect of glucagon treatment on plasma 
insulin concentration on d (1) postpartum. Glucagon 
increased plasma insulin. 
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Figure 11. Effect of glucagon treatment on plasma 
insulin concentration on d (7) postpartum. Glucagon 
increased plasma insulin. 
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Figure 12. Effect of glucagon treatment on plasma 
insulin concentration on d (13) postpartum. Glucagon 
increased plasma insulin. 
 
